Payment overview · 2025
General Payments
$363.34
15 reported records · 3 companies
Healthcare provider profile · identity verified
James K Tatum, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ALIQUIPPA, PA · NPI 1083647564
Verified facts
What the public records show
CMS Open Payments records show James K Tatum, M.D. received $363.34 in general payments during 2025 across 15 reported records.
AstraZeneca Pharmaceuticals LP accounted for 56.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $206.41 | 56.8% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $134.72 | 37.1% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.21 | 6.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $363.34 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $173.16 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $134.72 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 74 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 144 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
74 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
144 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1141 | 276 |
| Levothyroxine Sodium | Levothyroxine Sodium | 909 | 194 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 837 | 216 |
| Atorvastatin Calcium | Atorvastatin Calcium | 802 | 203 |
| Losartan Potassium | Losartan Potassium | 621 | 156 |
| Lisinopril | Lisinopril | 614 | 150 |
| Metformin Hcl | Metformin Hcl | 454 | 107 |
| Gabapentin | Gabapentin | 411 | 69 |
| Omeprazole | Omeprazole | 391 | 93 |
| Trazodone Hcl | Trazodone Hcl | 373 | 83 |
| Tamsulosin Hcl | Tamsulosin Hcl | 304 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 298 | 72 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 279 | 39 |
| Furosemide | Furosemide | 265 | 62 |
| Alprazolam | Alprazolam | 256 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 254 | 55 |
| Simvastatin | Simvastatin | 251 | 63 |
| Pravastatin Sodium | Pravastatin Sodium | 242 | 51 |
| Sertraline Hcl | Sertraline Hcl | 239 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 220 | 56 |
| Meloxicam | Meloxicam | 216 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 206 | 49 |
| Carvedilol | Carvedilol | 201 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 200 | 44 |
| Potassium Chloride | Potassium Chloride | 194 | 36 |
| Famotidine | Famotidine | 192 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 190 | 56 |
| Eliquis | Apixaban | 182 | 38 |
| Xarelto | Rivaroxaban | 163 | 25 |
| Ozempic | Semaglutide | 144 | 26 |
| Allopurinol | Allopurinol | 140 | 31 |
| Prednisone | Prednisone | 139 | 88 |
| Duloxetine Hcl | Duloxetine Hcl | 138 | 35 |
| Tramadol Hcl | Tramadol Hcl | 138 | 23 |
| Montelukast Sodium | Montelukast Sodium | 133 | 30 |
| Clonazepam | Clonazepam | 132 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 132 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 128 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 128 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 123 | 36 |
| Glipizide Er | Glipizide | 116 | 29 |
| Lorazepam | Lorazepam | 113 | 18 |
| Ezetimibe | Ezetimibe | 111 | 22 |
| Ibuprofen | Ibuprofen | 111 | 29 |
| Azithromycin | Azithromycin | 110 | 82 |
| Clonidine Hcl | Clonidine Hcl | 108 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 107 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 104 | 18 |
| Synthroid | Levothyroxine Sodium | 102 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 99 | 24 |
| Bupropion Hcl | Bupropion Hcl | 93 | 20 |
| Warfarin Sodium | Warfarin Sodium | 93 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 89 | 16 |
| Bupropion Xl | Bupropion Hcl | 86 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 86 | 15 |
| Levetiracetam | Levetiracetam | 86 | 14 |
| Finasteride | Finasteride | 83 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 81 | 17 |
| Trulicity | Dulaglutide | 80 | 15 |
| Atenolol | Atenolol | 78 | 21 |
| Farxiga | Dapagliflozin Propanediol | 74 | 14 |
| Novolog Flexpen | Insulin Aspart | 74 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 74 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 72 | 11 |
| Meclizine Hcl | Meclizine Hcl | 69 | 18 |
| Temazepam | Temazepam | 66 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 65 | 13 |
| Jardiance | Empagliflozin | 63 | 17 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 60 | 11 |
| Topiramate | Topiramate | 60 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 56 | 16 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 56 | 13 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 14 |
| Methocarbamol | Methocarbamol | 55 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 14 |
| Mounjaro | Tirzepatide | 54 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 54 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 53 | 14 |
| Linzess | Linaclotide | 53 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 53 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 14 |
| Ibu | Ibuprofen | 52 | 11 |
| Irbesartan | Irbesartan | 52 | 12 |
| Valacyclovir | Valacyclovir Hcl | 50 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | suppressed |
| Bumetanide | Bumetanide | 48 | suppressed |
| Mirtazapine | Mirtazapine | 48 | 13 |
| Amoxicillin | Amoxicillin | 46 | 26 |
| Glimepiride | Glimepiride | 46 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | suppressed |
| Spironolactone | Spironolactone | 44 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | suppressed |
| Baclofen | Baclofen | 42 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 41 | suppressed |
| Januvia | Sitagliptin Phosphate | 41 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 39 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 39 | 13 |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 39 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 38 | suppressed |
| Tradjenta | Linagliptin | 38 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 36 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | suppressed |
| Fluconazole | Fluconazole | 35 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Premarin | Estrogens, Conjugated | 34 | suppressed |
| Valsartan | Valsartan | 34 | 11 |
| Carisoprodol | Carisoprodol | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Celecoxib | Celecoxib | 31 | 11 |
| Cephalexin | Cephalexin | 30 | 12 |
| Diazepam | Diazepam | 30 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 19 |
| Labetalol Hcl | Labetalol Hcl | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Testosterone | Testosterone | 27 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 25 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 25 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Clotrimazole | Clotrimazole | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Jantoven | Warfarin Sodium | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Etodolac | Etodolac | 20 | suppressed |
| Lubiprostone | Lubiprostone | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Movantik | Naloxegol Oxalate | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Verapamil Sr | Verapamil Hcl | 16 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Minoxidil | Minoxidil | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $363.34 · 15 records | AstraZeneca Pharmaceuticals LP | FARXIGA, Ozempic, VOQUEZNA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error